MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have been assigned an average rating of "Buy" from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $74.50.

MLTX has been the topic of several recent research reports. Wedbush reissued an "outperform" rating and issued a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price on the stock in a research report on Monday, May 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $67.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Deutsche Bank AG increased its stake in shares of MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after purchasing an additional 338 shares during the last quarter. US Bancorp DE increased its holdings in shares of MoonLake Immunotherapeutics by 114.4% during the 1st quarter. US Bancorp DE now owns 2,208 shares of the company's stock worth $86,000 after acquiring an additional 1,178 shares during the last quarter. Quarry LP bought a new stake in MoonLake Immunotherapeutics in the 1st quarter valued at $94,000. Advisors Asset Management Inc. raised its stake in MoonLake Immunotherapeutics by 81.7% in the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock valued at $157,000 after acquiring an additional 1,803 shares during the period. Finally, Birchview Capital LP bought a new position in MoonLake Immunotherapeutics during the fourth quarter worth $217,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Trading Down 3.1%

Shares of MLTX stock traded down $1.50 on Friday, reaching $46.37. The company had a trading volume of 244,062 shares, compared to its average volume of 385,050. The stock has a market cap of $2.97 billion, a PE ratio of -20.16 and a beta of 1.27. The company has a 50-day moving average of $42.55 and a 200-day moving average of $42.75. The company has a current ratio of 21.11, a quick ratio of 21.11 and a debt-to-equity ratio of 0.18. MoonLake Immunotherapeutics has a 12 month low of $31.42 and a 12 month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period last year, the business earned ($0.22) earnings per share. On average, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.